ModifiedUnitedHealthcarePolicy CS064PA.S

Intensity‑Modulated Radiation Therapy (IMRT) (for Pennsylvania Only)

Policy governing coverage and medical necessity criteria for IMRT for adult members in Pennsylvania; applies to UnitedHealthcare Pennsylvania plans and outlines covered indications, documentation, and coding guidance.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity‑Modulated Radiation Therapy (IMRT) (for Pennsylvania Only)

Policy CodePolicy CS064PA.S

Change TypeCoverage additions and wording revisions

Effective DateMay 1, 2026

Next Review Date

Key ActionInclude documentation in prior authorization showing that IMRT is necessary to meet organ-at-risk constraints or that 3D-CRT cannot achieve adequate target coverage.

SourceLink

POLICY UPDATE CHANGES

Revised list of conditions for which IMRT for definitive therapy for the primary site is proven and medically necessary, including changes to breast cancer language and additions of several tumor types.

Added hepatocellular carcinoma (unresectable), Hodgkin lymphoma, intrahepatic cholangiocarcinoma (unresectable), rectal cancer when treatment involves inguinal lymph nodes, limited‑stage small cell lung cancer, retroperitoneal/intra‑abdominal soft tissue sarcoma, and Stage I–II NSCLC undergoing hypofractionated RT up to 10 fractions as proven and medically necessary indications.

Revised head and neck treatment area list replacing 'larynx (stage III or IV cancer)' with 'larynx' and added thyroid to examples of mediastinal tumors.

Removed statement that compensator‑based beam modulation is proven and medically necessary when combined with an IMRT indication listed as proven.

Reworded hippocampal‑avoidance whole brain radiation therapy from 'is proven and medically necessary' to 'is considered proven and medically necessary' when up to 10 fractions and criteria are met.

Replaced broader language about IMRT coverage for unlisted conditions to state IMRT 'may be considered medically necessary' for conditions not defined as proven and medically necessary.

Revised list of conditions considered proven and medically necessary for definitive IMRT, including additions such as unresectable hepatocellular carcinoma, Hodgkin lymphoma, and limited-stage small cell lung cancer.

Replaced prior wording about hippocampal-avoidance whole brain radiation therapy to state it is 'considered proven and medically necessary' when all listed criteria are met.

Clarified that IMRT may be considered medically necessary for conditions not defined as proven when certain conditions are met (rephrasing prior allowance language).

Added documentation language stating medical records may be required to assess coverage and must fully support medical necessity.

Updated coding guidance: added CPT codes 77407 and 77412 and removed CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Multiplenew indications added

19+document chunks in this part

>=19clinical indication examples

77407/77412coding updates

1policy history entries

Coverage Criteria and Clinical Indications

Hippocampal‑Avoidance Whole Brain RT (HA‑WBRT) with Memantine

Hippocampal‑avoidance whole‑brain radiation therapy (HA‑WBRT) with memantine is considered proven and medically necessary when ALL of the following are met:

Brain metastasis

Eastern Cooperative Oncology Group performance status of 3

Prognosis of four months or greater

Absence of leptomeningeal disease

No metastases within the hippocampal avoidance region (per guideline contouring), and use of memantine during/after WBRT per guideline dosing when appropriate

Mediastinal Hodgkin Lymphoma

Mediastinal Hodgkin lymphoma: IMRT (including VMAT) is considered proven and medically necessary when ALL of the following apply:

Diagnosis of Hodgkin lymphoma involving the mediastinum requiring radiation to the involved-site or involved-node volumes; and

Radiation planning demonstrates that IMRT provides superior target coverage or meaningful reduction in dose to critical organs-at-risk (eg, heart, coronary arteries, lungs, esophagus, and spinal cord) compared with 3D-CRT or AP/PA techniques; and

Appropriate techniques to minimize low‑dose bath (eg, deep-inspiration breath-hold, breath-hold, or other motion management) are considered where feasible

Use of IMRT/Advanced Techniques for Mediastinal, Thymic, Thyroid, and Lymphoma Cases

Use of IMRT or other advanced techniques for mediastinal, thymic, thyroid, and lymphoma cases is considered medically necessary when ALL of the following are met:

Tumor/anatomic location or prior therapy prevents achievement of treatment goals with 3D conformal techniques without exceeding normal tissue constraints; and

IMRT/VMAT or other advanced planning is expected to reduce clinically meaningful dose to OARs (eg, heart, lungs, thyroid, brachial plexus) compared with 3D‑CRT as shown on comparative planning; and

Daily image guidance and motion management (eg, 4D‑CT, breath hold) are used as appropriate to ensure accurate delivery

IMRT for Locally Advanced NSCLC

IMRT for locally advanced non-small cell lung cancer (NSCLC) is considered proven and medically necessary when ALL of the following are met:

Diagnosis of stage III (locally advanced) non-small cell lung cancer being treated with definitive chemoradiation; and

Comparative planning demonstrates IMRT will reduce dose to the heart and/or lungs (eg, lower heart V40, mean heart dose, or lower lung dose metrics) or reduce risk of grade 3 pneumonitis compared with 3D‑CRT; and

Motion management and image guidance are used during planning and treatment delivery

IMRT for Pancreatic and Thyroid Cancers

IMRT for pancreatic and thyroid cancers is considered proven and medically necessary when ALL of the following are met:

Pancreatic cancer: locally advanced or other indications where IMRT provides improved sparing of stomach/duodenum and allows adequate PTV coverage compared with 3D‑CRT (comparative plan required); and

Thyroid cancer: unresectable, postoperative high‑risk (R1/R2) or otherwise anatomically complex disease where IMRT improves target coverage or reduces dose to critical structures (eg, esophagus, spinal cord, larynx) compared with 3D‑CRT

Evidence Summaries by Disease Site

Evidence summaries by disease site (selected key points):

Anal cancer: RTOG 0529 (phase 2) and guideline recommendations support IMRT to reduce acute GI/dermatologic and hematologic toxicity while maintaining efficacy.

Breast cancer: randomized trials (Florence, NSABP B-39/RTOG 0413) and ASTRO guidance support APBI‑IMRT in selected early‑stage patients and IMRT (with DIBH when indicated) for internal mammary node coverage or PMRT when 3D‑CRT cannot meet constraints.

CNS tumors/HA‑WBRT: RCTs (eg, NRG CC001, Brown et al.) demonstrate HA‑WBRT plus memantine preserves cognition versus WBRT plus memantine without compromising intracranial control.

Cervical/Endometrial cancer: RCTs and guidelines (ASTRO, ESGO/ESTRO) support IMRT to reduce GI/GU toxicity with comparable oncologic outcomes.

Hepatobiliary (HCC/IHC): systematic reviews and ASTRO guidance support IMRT for dose‑escalated EBRT in unresectable disease with acceptable toxicity.

Indications and Clinical Considerations

Indications and clinical considerations — IMRT or advanced techniques may be appropriate when ONE or more of the following clinical considerations apply:

Need to spare nearby critical organs-at-risk to avoid exceeding established dose constraints (eg, heart, lungs, spinal cord, cochlea, hippocampi, brachial plexus);

Large or irregularly shaped target volumes where conformal dose sculpting improves target coverage and OAR sparing;

Reirradiation or prior radiation to adjacent/overlapping fields requiring precise dose shaping to limit cumulative normal tissue dose;

Use of hypofractionated or dose‑escalated regimens where precise dose delivery is needed to limit high‑dose exposure to OARs; and

Availability of image guidance, motion management, and quality assurance programs to support safe IMRT delivery

Evidence Limitations

Evidence limitations and caveats to consider when authorizing IMRT:

Many supportive data are from nonrandomized or retrospective studies for several disease sites; randomized evidence is limited for some indications.

IMRT can increase low‑dose exposure to larger volumes of normal tissue, which may raise long‑term risks such as secondary malignancies; balance benefits/risks, especially in younger patients.

Comparative planning (IMRT vs non‑IMRT) is frequently required to demonstrate clinically meaningful OAR dose reduction before approval for nonlisted or exception indications.

Hippocampal avoidance requires strict contouring and adherence to dose constraints; applicability is limited when metastases are within the hippocampal‑avoidance region.

Quality assurance, daily image guidance, and appropriate motion management are essential; lack of these may undermine expected benefit.

Considered Medically Necessary — Other Conditions

Considered Medically Necessary — Other Conditions: IMRT may be considered medically necessary on a case‑by‑case basis when ALL of the following are met:

The condition is not listed as a proven indication in this policy; and

Comparative treatment planning shows that IMRT meaningfully reduces predicted normal tissue toxicity (per RTOG/QUANTEC or similar constraints) compared with an appropriate non‑IMRT technique; or

The same or immediately adjacent area has been previously irradiated and IMRT is required to sculpt dose to avoid exceeding cumulative normal tissue tolerances; and

Sufficient clinical documentation is provided (history, prior radiation records if applicable, comparative dose–volume histograms, and justification for advanced technique)

Hippocampal‑Avoidance Whole Brain RT (HA‑WBRT)

Hippocampal‑avoidance whole‑brain RT (HA‑WBRT) — policy node (up to 10 fractions):

HA‑WBRT up to 10 fractions with concurrent or scheduled memantine is considered proven and medically necessary when ALL of the HA‑WBRT criteria above are met; and

Treatment planning must adhere to guideline hippocampal contouring and dose constraints, and use IMRT/VMAT techniques and daily image guidance to achieve sparing; and

Not appropriate when metastases are within the hippocampal‑avoidance region or in patients with leptomeningeal disease or very limited expected survival (< 4 months)

Procedure Codes, Billing Guidance, and Dose Information

Note

Coding Clarification / Billing guidance

Covered CPT CodesCPTCovered

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77407	Radiation treatment delivery; Level 2, single-isocenter (e.g., 3D or IMRT), photons, including imaging guidance, when performed.
77412	Radiation treatment delivery; Level 3, multiple isocenters with photon therapy or a single-isocenter photon therapy with active motion management, or total skin electrons, or mixed-electron/photon field(s), including imaging guidance, when performed.
77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.

Prior Authorization, Documentation, and Operational Requirements

Prior Authorization

Pennsylvania-specific prior authorization — case‑by‑case exception review

Requests not meeting the policy criteria will be evaluated case-by-case; exceptions may be granted when a plan comparison shows that a non‑IMRT technique would increase clinically meaningful normal tissue toxicity or when prior irradiation requires sculpting to avoid exceeding cumulative normal‑tissue tolerance.

Exceptions considered when plan comparison demonstrates IMRT reduces clinically meaningful OAR dose (RTOG/QUANTEC benchmarks)
Exceptions considered when same or immediately adjacent area was previously irradiated and sculpting is required to avoid cumulative tolerance

Prior Authorization

PA: justify choosing IMRT over 3D‑CRT

Prior authorization must include justification that IMRT/VMAT is required instead of 3D‑CRT — specifically documentation that IMRT will minimize toxicity or improve target coverage and planned image‑guidance when applicable.

Explain why 3D‑CRT cannot meet OAR constraints or target coverage

Background, Definitions, and Evidence Context

Intensity‑modulated radiation therapy (IMRT) is an advanced external beam radiation technique that modulates photon beam intensity across each beam to improve dose conformality to target volumes and spare adjacent normal tissues. IMRT is commonly paired with image‑guided radiation therapy (IGRT) and motion‑management strategies to verify target localization, reduce planning margins, and help meet organ‑at‑risk dose constraints; these capabilities underpin guideline recommendations and many of the proven/considered‑necessary indications cited in the policy.

Definitive Therapy — definition (policy-level)

Definitive Therapy — policy definitionRadiation treatments delivered with curative intent (definitive therapy) aiming to eliminate disease and achieve full recovery where appropriate

Definition sourcesDefinition referenced to NCCN (2025) and NCI curative‑intent definition

Policy applicationApplies to radiation delivered with curative intent as described in policy coverage criteria

DP-IMRT definition — dose-painted IMRT explanation and context

Policy Revision History

2026-05-01policy_revisionLatest

Revised coverage rationale: updated list of proven and medically necessary indications for definitive IMRT (breast phrasing revised; added unresectable hepatocellular carcinoma, Hodgkin lymphoma, unresectable intrahepatic cholangiocarcinoma, rectal cancer with inguinal nodal treatment, limited‑stage small cell lung cancer, retroperitoneal/intra‑abdominal soft tissue sarcoma, and Stage I–II NSCLC up to 10 fractions); head and neck and mediastinal examples revised; removed compensator‑based beam modulation language; hippocampal‑avoidance WBRT phrasing changed to 'considered proven and medically necessary'.

The revision history segment contains additional operational and documentation updates referenced elsewhere in the policy. These include added medical‑record documentation expectations, clarification of billing/coding guidance (CPT additions/removals), and summary notes describing the expanded list of proven/medically necessary indications and rewording of hippocampal‑avoidance WBRT phrasing; see the Policy History for full details.

This policy segment does not impose any step therapy sequencing requirements for IMRT. The document explicitly notes that no step therapy requirements are specified in this portion of the policy, and that IMRT may be considered when clinical criteria demonstrating superiority over less‑complex techniques are met.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity‑Modulated Radiation Therapy (IMRT) (for Pennsylvania Only)

Policy CodePolicy CS064PA.S

Change TypeCoverage additions and wording revisions

Effective DateMay 1, 2026

Next Review Date

Key ActionInclude documentation in prior authorization showing that IMRT is necessary to meet organ-at-risk constraints or that 3D-CRT cannot achieve adequate target coverage.

SourceLink

On This Page

Hodgkin/mediastinal lymphoma: comparative studies and ILROG guidance support IMRT to improve OAR sparing for complex mediastinal anatomy.

NSCLC: RTOG 0617 secondary analyses and guidelines support IMRT for stage III to reduce cardiac and pulmonary dose and lower severe pneumonitis rates.

Pancreatic cancer: retrospective studies and ASTRO guidance support IMRT to reduce GI toxicity compared with 3D‑CRT while maintaining tumor coverage.

Document planned IGRT/verification methods when IMRT/VMAT is proposed

Prior Authorization

Prior auth when CT‑based 3D‑CRT is insufficient

Obtain prior authorization when IMRT is selected because CT‑based 3D techniques cannot meet organ‑at‑risk constraints; include documentation showing 3D plans failed to meet constraints and that IMRT is needed to spare critical structures.

Show comparison demonstrating 3D‑CRT cannot adequately limit dose to heart, lungs, bowel, or other critical OARs
Provide dosimetric evidence that IMRT achieves required OAR limits

Prior Authorization

Prior auth must reflect guideline‑supported IMRT for head & neck

Prior authorization should align with guideline recommendations (NCCN, ASTRO) that prefer IMRT for multiple head & neck subsites; include tumor site and organ‑at‑risk rationale consistent with guideline‑recommended technique selection.

State guideline basis (e.g., NCCN/ASTRO) for IMRT at the treated head/neck subsite
Document OARs at risk and how IMRT will reduce exposure (mandible, salivary glands, pharyngeal constrictors)

Prior Authorization

Prior auth: guideline‑aligned use (liver, HA‑WBRT)

For indications supported by guidelines (e.g., unresectable liver tumors, HA‑WBRT when hippocampus is uninvolved), prior authorization should document that criteria for IMRT/HA‑WBRT are met, including prognosis and absence of hippocampal lesions for HA‑WBRT.

For HA‑WBRT, document expected survival ≥4 months and no metastases within 5 mm of hippocampus
For liver HCC/IHC, document unresectable status and rationale for EBRT/IMRT per ASTRO/NCCN guidance

Prior Authorization

Prior auth: document consideration of CT‑based 3D‑CRT and need for advanced technique

Document that CT‑based 3D‑CRT was considered and that advanced techniques (IMRT/VMAT/IGRT or motion management) are necessary to meet OAR constraints or safely deliver curative therapy.

Include rationale and comparison showing 3D‑CRT plan limitations
List planned advanced delivery and motion‑management techniques (DIBH, 4D‑CT, gating)

Prior Authorization

Prior auth for rectal cancer reirradiation/complex nodal anatomy

When reirradiation, recurrent disease, postoperative treatment with increased toxicity risk, or anatomically complex nodal involvement (e.g., inguinal or pelvic external iliac nodes) is planned, include prior‑treatment details and imaging/plan documentation to justify IMRT.

Provide prior radiation records and cumulative dose assessment
Include imaging and dosimetric plan comparisons showing IMRT needed for safe reirradiation or complex nodal coverage

Prior Authorization

Prior auth: include planning and intended dose‑constraint rationale

Prior authorization must include clinical rationale and intended dose/fractionation demonstrating that IMRT is required to meet target coverage while respecting normal‑tissue dose constraints; include planned dose constraints and expected OAR dosimetry.

State intended prescription and relevant OAR dose constraints (e.g., heart V40/V50 targets)
Explain how IMRT enables achieving tumor coverage without exceeding normal‑tissue limits

Prior Authorization

Prior auth must match revised proven/considered indications

Ensure prior authorization requests and approvals reflect the policy's revised indications and updated wording that IMRT may be 'considered medically necessary' for conditions not listed as proven; cite the specific revised indication when applicable.

Reference the updated list of proven/considered indications in the policy revision
If relying on 'considered medically necessary' language, provide supporting clinical justification

Billing Rule

Prior auth and coding: document clinical criteria and justify CPT level

Prior authorization may require clinical documentation to support medical‑necessity criteria; billing guidance indicates standard single‑isocenter IMRT/VMAT should be billed under CPT 77407 and complex deliveries (multiple isocenters or active motion management) under CPT 77412 with documentation justifying level 3 billing.

Provide documentation justifying 77412 when multiple isocenters or active motion‑management are used
Include clinical justification and plan details when submitting authorization for billing level

Prior Authorization

Consideration of IMRT for unlisted indications when superiority is demonstrated

IMRT may be considered medically necessary for conditions not explicitly listed when preauthorization documentation demonstrates that IMRT provides superiority over non‑IMRT (e.g., reduces clinically meaningful normal‑tissue toxicity on plan comparison) — such cases are reviewed individually.

Provide plan comparisons showing clinically meaningful OAR dose reduction with IMRT
Show circumstances such as prior radiation or anatomical constraints that favor IMRT

Step Therapy

No step‑therapy or mandated sequencing specified

No step‑therapy or sequencing requirements are specified in these policy excerpts; authorization decisions should follow the clinical criteria and case‑by‑case exception provisions instead of mandatory sequencing.

No mandatory prior use of less‑complex techniques is required by the policy excerpts
Clinical sequencing (e.g., induction chemo then consolidation RT for IHC) should follow guideline recommendations rather than payer step therapy

Documentation Required

Document preference rationale when 3D‑CRT could meet objectives

If CT‑based 3D‑CRT can meet target and OAR objectives, document why IMRT is nevertheless preferred — include contraindications to 3D‑CRT or advantages of IMRT for sparing critical OARs or enabling necessary techniques (e.g., DIBH, IGRT).

Provide comparative planning showing 3D‑CRT adequacy or why it is inadequate
Document patient‑specific reasons for preferring IMRT (proximity to OARs, reconstruction, motion management)

Note

Technique selection: 3D‑CRT acceptable when constraints met; prefer IMRT if inadequate

Select 3D‑CRT when dose constraints and target coverage can be met; elect IMRT when 3D techniques are inadequate to spare critical OARs — document the decision‑making and dosimetric comparisons used.

Show that 3D‑CRT meets constraints when chosen
If IMRT chosen, document why 3D‑CRT would fail to spare heart, lungs, bowel, or other critical OARs

Step Therapy

No mandated step therapy — use evidence to guide technique selection

Evidence supports IMRT over 2D/3D techniques for reducing toxicity in appropriate indications; the policy does not impose step therapy requiring progression through less‑complex techniques before IMRT when clinically indicated.

Use IMRT when guideline and evidence‑based indications favor toxicity reduction over 2D/3D approaches
No required trial of 3D‑CRT is mandated when IMRT is clinically indicated

Documentation Required

Imaging and IGRT documentation expected for intrahepatic IMRT/SBRT

For intrahepatic treatments and liver SBRT/IMRT, document use of advanced simulation/motion‑management imaging and IGRT (eg, 4D‑CT, PET/CT) at simulation and delivery as expected per guidelines to ensure accurate target coverage and minimize liver toxicity.

Include type of simulation imaging (4D‑CT, PET/CT) and motion‑management approach
Document planned IGRT methods to be used during delivery

Documentation Required

Medical‑record documentation requirement to support medical necessity

Document the clinical history, exam findings, diagnostic test results, and other relevant records in the medical record to fully support medical necessity; records must be legible and made available upon request for prior authorization or review.

Include relevant medical history, physical examination, and diagnostic test/procedure results
Ensure documentation is legible, maintained in the record, and available on request

Documentation Required

Document guideline implementation: daily IGRT and recommended fractionation

Follow guideline implementation notes: daily image guidance is encouraged with IMRT for verification of target localization, and use recommended fractionation regimens where specified (eg, APBI regimens per ASTRO) — document planned IGRT and fractionation.

Document planned daily IGRT/verification approach
When using APBI/partial‑breast regimens, document selected ASTRO‑recommended fractionation (e.g., 3000 cGy in 5 fractions)

Documentation Required

Document rationale and techniques when selecting IMRT/VMAT

When selecting IMRT/VMAT, explicitly document why CT‑based 3D‑CRT is insufficient and list the advanced planning/delivery techniques to be used (IGRT, DIBH, SIB, motion management) and planned dose constraints.

Provide dosimetric comparison and state which OAR constraints cannot be met with 3D‑CRT
List planned techniques (IGRT, DIBH, VMAT, SIB) and intended constraints

Documentation Required

Treatment planning and IGRT documentation for nodal/para‑aortic cases

Support IMRT use with documentation of treatment planning, IGRT, and justification when treating para‑aortic nodes or gross nodal disease — include simulation method, motion management, and how IGRT will be used to verify delivery.

Include CT‑based simulation details and IGRT method (cone‑beam CT, orthogonal imaging)
Document motion management or respiratory control if applicable

Documentation Required

Document OAR dose‑sparing rationale for head & neck (mandible/maxilla)

For head & neck cases, document OAR dose‑sparing rationale (eg, mandible/maxilla constraints) and plans to reduce osteoradionecrosis risk when IMRT is used to minimize dose to jaw structures.

State proximity of tumor to mandible/maxilla and planned mandibular dose constraints
Explain how IMRT planning reduces osteoradionecrosis risk

Documentation Required

Required clinical documentation elements (tumor site, hippocampal proximity, rationale, fractionation)

Include required clinical elements in the record: tumor location, presence/absence of lesions near avoidance regions (eg, hippocampus within 5 mm), rationale for IMRT/HA‑WBRT, and planned fractionation and image guidance.

Specify whether hippocampus is within 5 mm of any metastasis for HA‑WBRT eligibility
Include treatment intent, fractionation, and planned image guidance

Documentation Required

Dosimetric justification and CT‑simulation documentation

Provide CT‑based simulation and dosimetric comparisons demonstrating that IMRT/VMAT materially reduces dose to organs at risk or is required for complex anatomy or large PTVs to meet dose constraints while preserving target coverage.

Include CT simulation details and plan comparison DVHs
Show how IMRT meets OAR constraints when 3D‑CRT cannot

Documentation Required

Document guideline‑aligned rationale (intent, fractionation, IGRT)

Document how the proposed treatment aligns with guideline recommendations: state treatment intent, fractionation, use of image guidance, and the guideline basis for recommending IMRT when applicable.

Cite relevant guideline(s) (ASTRO, NCCN, ACR) supporting IMRT choice
List image‑guidance and fractionation consistent with guideline recommendations

Documentation Required

Document advanced simulation and motion‑management imaging for intrahepatic cases

Use advanced simulation and motion‑management imaging (eg, 4D‑CT, PET/CT) and document their use when delivering IMRT to intrahepatic tumors to ensure adequate coverage and OAR sparing.

Document specific simulation modalities used (4D‑CT, PET/CT) and motion‑management strategy
Include IGRT approach to be used during treatment delivery

Documentation Required

Document that clinical indication matches updated proven/medically necessary list

Support the clinical indication by documenting that the patient meets the policy's updated list of proven/medically necessary conditions when claiming coverage under a revised indication.

Reference the specific revised proven/medically necessary indication in the request
Attach supporting clinical records demonstrating the indication matches policy criteria

Denial Risk

Provide full medical‑record documentation or risk denial

Medical records must fully support medical necessity and may be required for review; failure to provide adequate documentation may lead to denial or need for additional review.

Ensure all requested supporting records are available and legible upon request
Be prepared to supply prior radiation records and dosimetry for cumulative dose assessment

Denial Risk

Denial risk for lack of supporting medical‑record documentation

Absent adequate documentation supporting medical necessity, prior authorization or claims may be denied or require further review; ensure all required elements (history, exam, diagnostics, dosimetry) are included.

Incomplete or missing documentation may result in denial or requests for additional information
Maintain legible records of history, exam, diagnostic tests, and dosimetric plan comparisons

Documentation Required

Document prior radiation and cumulative normal‑tissue dose

Consider prior radiation and cumulative normal‑tissue toxicity in authorization requests; failure to document prior radiation fields and cumulative doses may adversely affect coverage decisions.

Provide prior treatment records and cumulative dose calculations when relevant
Explain how IMRT will avoid exceeding cumulative tolerance of nearby normal tissues

Denial Risk

Caution: do not substitute IMRT for brachytherapy in intact cervix without justification

IMRT should not routinely replace brachytherapy for central cervical disease in patients with an intact cervix; prior authorization should justify deviation from brachytherapy when proposed as a substitute.

If proposing IMRT in lieu of brachytherapy for intact cervix, provide strong justification and rationale
Reference guideline statement that brachytherapy remains essential for central disease

Documentation Required

IGRT expected for liver IMRT/SBRT — document method

When delivering IMRT or SBRT for intrahepatic tumors, document and use IGRT per guideline expectations to enhance precision and minimize toxicity; omission may conflict with guideline recommendations and affect authorization.

Specify IGRT modalities to be used (cone‑beam CT, orthogonal imaging)
Document center expertise in delivering hypofractionated liver RT with IGRT

Denial Risk

Combined IMRT+PBRT in same plan is unsupported — risk of denial

Do not propose combined IMRT and proton beam therapy within a single treatment plan — the literature does not support combined‑plan delivery and such requests may be denied.

Avoid billing/authorization requests that combine IMRT and PBRT in the same plan
If proposing mixed‑modality approaches, provide compelling evidence and rationale

Denial Risk

Avoid relying on removed/obsolete indications (compensator‑based modulation)

Requests relying on language removed from the policy (eg, compensator‑based beam modulation described previously as proven when combined with IMRT) may be at risk; ensure authorization references current policy language and indications.

Do not cite removed compensator‑based modulation language when justifying coverage
Align requests with the revised proven/considered indications list

Denial Risk

Documentation‑related denial risk for incomplete records

Lack of required supporting documentation (history, exam, diagnostics, dosimetry) may result in denial or inability to approve requested services; ensure records are complete and legible.

Ensure all clinical, imaging, and dosimetric documentation is included with the request
Maintain legible and retrievable medical records for review

DP‑IMRT definitionDose‑painted IMRT (DP‑IMRT): IMRT delivered with differential dose levels to target subvolumes (as used in RTOG 0529 for anal cancer)

Clinical contextUsed to tailor doses by stage and nodal involvement (eg, higher dose to bulky disease and lower dose to elective nodes)

Example dosingRTOG 0529 used 42 Gy to elective nodes and 50.4–54 Gy to primary/ involved nodes depending on stage

APBI — accelerated partial-breast irradiation definition and examples

APBI definitionAccelerated partial‑breast irradiation (APBI): radiation targeting the tumor bed rather than the whole breast, delivered in a shortened schedule

Common APBI regimensExamples include 30 Gy in 5 once‑daily fractions (Florence trial) and 4,005 cGy in 15 once‑daily fractions (ASTRO guidance)

Technique noteAPBI can be delivered with external‑beam IMRT per guideline recommendations for selected early‑stage patients

PMRT / Postmastectomy radiation therapy — definition and scope

PMRT definitionPostmastectomy radiation therapy (PMRT): radiation targeting the chest wall and ipsilateral regional nodes (axillary, supraclavicular, infraclavicular, internal mammary) after mastectomy

Indications and technique notesRecommended for node‑positive disease and pT4 tumors; IMRT/VMAT is used when 3D‑CRT cannot meet target or OAR constraints

Fractionation and reconstructionModerate hypofractionation preferred for patients without reconstruction; for reconstructed patients moderate hypofractionation or conventional fractionation may be used

IGRT definition — daily imaging to ensure target coverage

IGRT definitionImage‑guided radiation therapy (IGRT): use of daily imaging (orthogonal imaging, cone‑beam CT, or other volumetric imaging) at time of treatment delivery to ensure target coverage and spare normal tissues

Recommended useIGRT is essential with IMRT for pelvic and breast treatments and when treating para‑aortic nodes or gross nodal disease

PurposeAccounts for motion, reduces margins, and verifies setup to meet OAR constraints

IGRT (alternate) — IGRT used with IMRT to account for motion and spare OARs

IGRT (alternate) definitionIGRT used with IMRT to ensure accurate dose delivery, account for motion, reduce margins, and spare organs at risk

Planning implicationsSupports use of cone‑beam CT or surface guidance and is recommended for pelvic, breast, and liver IMRT per guidelines

DocumentationPolicy expects documentation of IGRT use in prior authorization and treatment records when indicated

DO-IMRT — dysphagia-optimized IMRT definition

DO‑IMRT definitionDysphagia‑optimized IMRT (DO‑IMRT): an IMRT planning approach that specifically reduces dose to swallowing‑related structures to improve swallowing outcomes

Clinical evidenceValidated in a phase 3 RCT (Nutting et al.) showing improved MDADI scores at 12 and 24 months versus standard IMRT

Target structuresPlanning focuses on pharyngeal constrictors and other dysphagia‑related anatomy

Dysphagia-optimized IMRT (DO-IMRT) — planning approach to reduce dose to swallowing structures

DO‑IMRT planning approachPlanning intentionally reduces dose to pharyngeal constrictors and aspiration‑related structures while maintaining tumor coverage to improve patient‑reported swallowing function

Evidence basePhase 3 DO‑IMRT trial demonstrated sustained improvements in swallowing‑related quality of life measures

Implementation noteRequires contouring of swallowing structures and dosimetric trade‑offs documented in the plan

HA-WBRT — hippocampal-avoidance whole-brain RT definition and margin mention

HA‑WBRT definitionHippocampal‑avoidance whole‑brain radiation therapy (HA‑WBRT): WBRT technique that intentionally spares the hippocampal neurogenic niche (with an avoidance margin typically 3–7 mm) to reduce cognitive decline

Concomitant therapyOften delivered with memantine per guideline and trial protocols

Technical requirementRequires IMRT/advanced planning and IGRT to meet hippocampal dose constraints

IMRT/VMAT and advanced techniques — definition/context for paired technologies

IMRT/VMAT and advanced techniques — definitionHighly conformal external beam radiotherapy techniques (IMRT, VMAT) often paired with IGRT, respiratory motion management (DIBH, gating, 4D‑CT), and image guidance to reduce dose to organs at risk while maintaining target coverage

Clinical roleUsed for complex thoracic, mediastinal, head and neck, and breast cases where OAR sparing is critical

Planning implicationMay increase low‑dose bath to surrounding tissues; benefits require dosimetric justification versus 3D‑CRT

IMRT/VMAT definition — planning/delivery techniques used for hypofractionation and conventional schedules

IMRT/VMAT definitionModulated treatment techniques used for planning and delivery of conventionally fractionated and hypofractionated radiation therapy to improve conformality and spare OARs

Typical usesRecommended for localized pancreatic cancer, prostate cancer, and other sites per ASTRO/ACR guidance

Technical noteUsually implemented with inverse planning, multileaf collimation, and QA processes specific to modulated delivery

Freedom from biochemical failure (prostate) — Phoenix criteria definition

Freedom from biochemical failure (Phoenix) definitionPhoenix criteria: PSA nadir + 2 ng/mL defines biochemical failure used to measure freedom from biochemical failure in prostate trials

ContextUsed as primary outcome in prostate IMRT vs 3D‑CRT randomized trial cited in policy

Clinical relevanceStandard measure for biochemical recurrence in definitive prostate radiotherapy studies

BED10 — definition and use in SCLC dose-escalation context

BED10 definition and useBED10: biologically effective dose calculated with α/β = 10; used to categorize dose escalation in thoracic/SCLC studies (eg, BED10 >70 Gy denotes escalated dosing)

Clinical applicationApplied in retrospective SCLC dose‑escalation analyses comparing standard vs escalated groups

InterpretationBED10 allows comparison of different fractionation regimens on a common biologic scale

NCCN Clinical Practice Guidelines — citation note and role in supporting indications

NCCN guidelines — roleNCCN Clinical Practice Guidelines are cited throughout the policy as tumor‑specific guidance supporting indications and technique selection for IMRT

Support examplesNCCN recommendations referenced for head and neck, breast, NSCLC, HCC, and other disease‑specific guidance

Implementation notePolicy aligns coverage decisions with NCCN and other professional society guidance where applicable

Definitive Therapy — updated definition referenced in revision

Updated Definitive Therapy definitionPolicy updated the definition of 'Definitive Therapy' in this revision (definitive therapy denotes curative‑intent radiation treatments)

Operational impactRevised definition is referenced in coverage rationale and applicability to adults (19+) in policy

SourceDefinition update noted in policy history and supported by NCCN/NCI definitions

Coding updates made in this revision are summarized in the Policy History and are reflected in the coding section of the policy. Notably, CPT codes 77407 and 77412 were added (with guidance about single‑isocenter versus complex/multiple‑isocenter deliveries), and CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017 were removed; these changes are recorded in the revision notes and the coding blocks.